10 IPOs entered the public market this past week headlined by Airbnb (ABNB) and DoorDash (DASH), which completed the largest and second-largest IPOs of 2020, respectively. They were joined by 20 blank check IPOs in the busiest week for SPACs ever. New...read more
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised $193 million by offering 8.4 million shares at $23, the high end of the upwardly revised range of $22 to $23. The company offered 1.4 million more...read more
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-based company now plans to raise $158 million by offering 7 million...read more
4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, announced terms for its IPO on Monday. The Emeryville, CA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22....read more
US IPO Weekly Recap: Airbnb and DoorDash make their public debuts in a 10 IPO week
10 IPOs entered the public market this past week headlined by Airbnb (ABNB) and DoorDash (DASH), which completed the largest and second-largest IPOs of 2020, respectively. They were joined by 20 blank check IPOs in the busiest week for SPACs ever. New...read more
Gene therapy biotech 4D Molecular Therapeutics prices further upsized IPO at $23, the high end of the upwardly revised range
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised $193 million by offering 8.4 million shares at $23, the high end of the upwardly revised range of $22 to $23. The company offered 1.4 million more...read more
Gene therapy developer 4D Molecular Therapeutics increases deal size by 58% ahead of $158 million IPO
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-based company now plans to raise $158 million by offering 7 million...read more
Gene therapy developer 4D Molecular Therapeutics sets terms for $100 million IPO
4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, announced terms for its IPO on Monday. The Emeryville, CA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22....read more